August 16, 2012
Pfizer Japan announced on August 10 that an additional indication of pancreatic neuroendocrine tumors (pNET) for the anticancer agent Sutent (sunitinib) was approved on the same day. According to the company, pNET accounts for 1% to 2% of all pancreatic...read more